deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01639001

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS

Sponsor: Pfizer

Conditions NSCLC (Non-small Cell Lung Cancer)
Interventions Crizotinib Pemetrexed/Carboplatin Pemetrexed/Cisplatin
Updated 15 times since 2017 Last updated: Nov 16, 2020 Started: Sep 29, 2012 Primary completion: Jun 30, 2015 Completion: Jan 8, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01639001, this PHASE3 trial focuses on NSCLC (Non-small Cell Lung Cancer) and remains completed. Sponsored by Pfizer, it has been updated 15 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Aug 2020 · 11 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

15 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. May 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bangkok, Thailand , Beijing, China , Chai Wan, Hong Kong , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , George Town, Malaysia , Guangzhou, China and 17 more locations